Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Lilly goes cellular for $34m
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
Nkarta goes back to basics
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.
ADA 2023 – Vertex raises hopes of type 1 diabetes cure
But it still has a long way to go with its islet cell therapies.
Cartesian maps the path for an autoimmune disease cell therapy
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Uniqure’s accelerated approval hopes take a hit
Despite showing arguable signals of efficacy Uniqure’s Huntington’s disease gene therapy has some fundamental problems.